Panbela Therapeutics (PBLA) AI Stock Analysis

• Market Cap: $1.56M
• Dividend Yield: N/A
• Average Volume (3M): 16.03K
• Price to Earnings (P/E): ―
• Beta (1Y): -0.31
• Revenue Growth: N/A
• EPS Growth: 99.19%
• Country: US
• Employees: 7
• Sector: Healthcare
• Sector Strength: 64
• Industry: Biotechnology
• EPS (TTM): -32.52
• Shares Outstanding: 4,854,831
• 10 Day Avg. Volume: 14,653
• 30 Day Avg. Volume: 16,026
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• Price to Cash Flow (P/CF): -0.20
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

Panbela Therapeutics faces significant financial instability, with no revenue and negative equity, which are major concerns. While there are positive developments in clinical trials and strategic investments, the ongoing financial challenges and reliance on external funding heavily weigh down the score. The technical indicators and valuation metrics provide little support, reflecting limited investor confidence.

Panbela Therapeutics Business Overview & Revenue Model

Company Description

Panbela Therapeutics, Inc., a clinical-stage biopharmaceutical company, together with its subsidiaries, focuses on developing disruptive therapeutics for the treatment of patients with cancer. The company focuses on diseases of the pancreas, including pancreatitis and pancreatic cancer, as well as neoadjuvant pancreatic cancer, colorectal cancer, ovarian cancer, and other agents in other cancer indications. Its lead product candidate is SBP-101, which is in Phase Ia/Ib clinical trial for the treatment of patients with metastatic pancreatic ductal adenocarcinoma. The company was formerly known as Sun BioPharma, Inc. and changed its name to Panbela Therapeutics, Inc. in December 2020. Panbela Therapeutics, Inc. was incorporated in 2011 and is based in Waconia, Minnesota.

How the Company Makes Money

Panbela Therapeutics generates revenue primarily through the development and commercialization of its proprietary cancer therapies. The company invests heavily in research and development to bring its innovations from the lab to the market. Potential revenue streams include licensing agreements with larger pharmaceutical companies, milestone payments based on the achievement of clinical and regulatory benchmarks, and future sales of approved therapies. Panbela may also receive funding through strategic partnerships, grants, and potential collaborations with academic and research institutions dedicated to cancer treatment advancements. As these therapies progress through clinical trials and regulatory approvals, Panbela aims to establish a robust market presence and generate significant revenue from the commercial distribution of its products.

Panbela Therapeutics Financial Statement Overview

Summary

Panbela Therapeutics is facing significant financial challenges with no revenue and consistent losses, leading to negative equity and a reliance on financing for cash flow. The biotechnology industry often requires substantial investment before profitability; however, the current trajectory highlights significant financial instability and risk.

Income Statement

Panbela Therapeutics has consistently reported negative gross profit, EBIT, and net income over the past several years, with no revenue generated. This indicates a challenging financial position with high operational costs and no income to offset these expenses. The company lacks revenue growth, which is crucial for financial improvement.

Balance Sheet

The company's balance sheet shows negative stockholders' equity, indicating liabilities exceed assets. The debt-to-equity ratio cannot be calculated due to negative equity, posing a risk of insolvency. The equity ratio is also negative, reflecting weak financial stability.

Cash Flow

Panbela Therapeutics has negative free cash flow, suggesting it is not generating enough cash to sustain operations and relies heavily on financing activities. However, the company has maintained some cash flow through financing, which indicates a potential to manage short-term liquidity needs.

Breakdown
TTM	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019
Income Statement		Total Revenue
0.00	0.00	0.00	0.00	0.00	0.00
	Gross Profit
-29.04M	-25.65M	-35.73M	-10.01M	-5.75M	-4.32M
	EBIT
-36.20M	-51.29M	-34.09M	-10.01M	-5.75M	-4.32M
	EBITDA
-27.43M	-51.29M	-34.76M	-10.61M	-5.15M	-4.42M
	Net Income Common Stockholders
-27.91M	-25.26M	-34.93M	-10.13M	-4.77M	-6.20M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
1.41M	2.58M	1.28M	11.87M	9.02M	2.45M
	Total Assets
1.90M	11.80M	4.98M	12.87M	9.81M	3.14M
	Total Debt
350.00K	5.19M	6.84M	0.00	0.00	116.00K
	Net Debt
-1.05M	2.62M	5.56M	-11.87M	-9.02M	-2.33M
	Total Liabilities
1.63M	16.51M	13.03M	2.66M	1.36M	1.76M
	Stockholders Equity
268.00K	-4.71M	-8.05M	10.21M	8.45M	1.39M
Cash Flow		Free Cash Flow
-15.57M	-25.25M	-15.94M	-6.70M	-3.85M	-2.74M
	Operating Cash Flow
-15.57M	-25.25M	-15.28M	-6.70M	-3.85M	-2.74M
	Investing Cash Flow
-7.97M	400.00K	-656.00K	-540.00K	0.00	0.00
	Financing Cash Flow
14.03M	26.14M	5.35M	10.10M	10.44M	3.78M

Panbela Therapeutics Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.34
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PBLA, the sentiment is Positive. The current price of 0.34 is above the 20-day moving average (MA) of 0.32, below the 50-day MA of 0.34, and below the 200-day MA of 0.35, indicating a neutral trend. The MACD of -0.02 indicates Positive momentum. The RSI at 49.43 is Neutral, neither overbought nor oversold. The STOCH value of 37.72 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for PBLA.

Panbela Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$5.20B	3.18	-40.80%	2.96%	17.66%	1.94%
APVO	38 Underperform	$2.05M	―	-284.28%	―	―	83.04%
PBLA	37 Underperform	$1.56M	―	153.59%	―	―	99.19%
VRPX	31 Underperform	$372.75K	―	-2364.82%	―	―	60.26%
SLRX	30 Underperform	$1.40M	―	-164.02%	―	―	79.57%
ZVSA	29 Underperform	$2.53M	―	-96.10%	―	―	99.39%
PTIX	27 Underperform	$1.57M	―	-236.06%	―	―	-40.51%